Table 2 Primary endpoints of spleen volume response rate >35% (SVR35) and symptom response (reduction in symptoms >50%) at week 24 in a subgroup analysis of patients enrolled in the JAKARTA and JAKARTA-2 trials with low baseline platelets (50 000–100 000/µL) vs high baseline platelets (>100,000/µL).

From: Fedratinib for the treatment of myelofibrosis: a critical appraisal of clinical trial and “real-world” data